Ionis Pharmaceuticals Inc (IONS) : Simplex Trading scooped up 40,534 additional shares in Ionis Pharmaceuticals Inc during the most recent quarter end , the firm said in a disclosure report filed with the SEC on Oct 7, 2016. The investment management firm now holds a total of 47,310 shares of Ionis Pharmaceuticals Inc which is valued at $1,620,841.Ionis Pharmaceuticals Inc makes up approximately 0.21% of Simplex Trading’s portfolio.
Other Hedge Funds, Including , Advisory Services Network reduced its stake in IONS by selling 200 shares or 15.81% in the most recent quarter. The Hedge Fund company now holds 1,065 shares of IONS which is valued at $36,487. Ionis Pharmaceuticals Inc makes up approx 0.01% of Advisory Services Network’s portfolio.Bnp Paribas Arbitrage Sa boosted its stake in IONS in the latest quarter, The investment management firm added 32,982 additional shares and now holds a total of 51,100 shares of Ionis Pharmaceuticals Inc which is valued at $1,859,018. Ionis Pharmaceuticals Inc makes up approx 0.01% of Bnp Paribas Arbitrage Sa’s portfolio.Washington Trust Bank reduced its stake in IONS by selling 6 shares or 23.08% in the most recent quarter. The Hedge Fund company now holds 20 shares of IONS which is valued at $728.
On the company’s financial health, Ionis Pharmaceuticals Inc reported $-0.47 EPS for the quarter, beating the analyst consensus estimate by $ 0.03 according to the earnings call on Aug 9, 2016. Analyst had a consensus of $-0.50. The company had revenue of $38.50 million for the quarter, compared to analysts expectations of $38.45 million. The company’s revenue was down -68.0 % compared to the same quarter last year.
Many Wall Street Analysts have commented on Ionis Pharmaceuticals Inc. Company shares were Reiterated by Piper Jaffray on Aug 10, 2016 to “Overweight”, Firm has raised the Price Target to $ 46 from a previous price target of $36 .Morgan Stanley Initiated Ionis Pharmaceuticals Inc on Aug 3, 2016 to “Equal-Weight”, Price Target of the shares are set at $37.Company shares were Reiterated by Needham on Aug 2, 2016 to “Buy”, Firm has raised the Price Target to $ 64 from a previous price target of $55 .
Ionis Pharmaceuticals Inc. formerly Isis Pharmaceuticals Inc. is a ribonucleic acid-targeted (RNA-targeted) drug discovery and development company. The Company is focused on discovering and developing antisense drugs. Its antisense drugs are used to treat a range of diseases including cardiovascular; metabolic; severe and rare diseases including neurological disorders and cancer. Volanesorsen is a drug indicated to treat patients with high triglyceride levels including patients with a genetic condition called familial chylomicronemia syndrome (FCS) and patients with partial lipodystrophy. It is focused on bringing its late-stage Phase III drugs nusinersen volanesorsen and IONIS-TTR to the market. Its lipid-lowering product KYNAMRO (mipomersen sodium) injection is on the market in the United States for patients with homozygous familial hypercholesterolemia (HoFH). Its products also include Alicaforsen IONIS-DMPK-2.5 Plazomicin and IONIS-GCGR.